properties of cancer cells, such as cell proliferation, cell invasion and migration, cell adhesion, and metastasis. [15] [16] [17] In contrast, monosialyl gangliosides, such as GM1, GM3, and GM2 often suppress malignant properties of various cancer cells. [18] [19] [20] Therefore, GD3 synthase is a key enzyme determining cell phenotypes based on the expression patterns of gangliosides, as shown in Figure 1 .
| ENI G MA IN THE AC TI ON MECHANIS MS FOR G LYCOS PHING OLIPIDS HA S B EEN G E T TING D ISCLOS ED
How these glycosphingolipids affect the phenotypes and behaviors of cells in various manners has also been rigorously analyzed, and molecular mechanisms by which glycosphingolipids modify cell signaling based on the interaction with other molecules existing on the same membrane (cis-binding) or on the different cell surface (transbinding) have been reported. 21 Although soluble and/or cell surface ligand molecules that gain access from outside cells are important as trans-interacting molecules with glycosphingolipids, 22 knowledge on cis-interaction on the cell surface has recently advanced. In this group, growth factor receptors and adhesion receptors such as the integrin family are mainly defined as cis-interacting molecules with glycosphingolipids on the cell surface, leading to the modification of cell signals mediated by those receptors 16, 17 ( Figure 2 ). In Figure 2A , 
16,17
Results on increased adhesion signals by the integrin-FAK axis are presented in Figure 2B .
The recent development of a new approach to define interacting molecules with cancer-associated glycosphingolipids on the surface of living cells has markedly promoted understanding of these interactions, namely EMARS/MS, developed by Honke and Kotani. 23 To analyze molecular clustering on the cell surface, coimmunoprecipitation has been used. Cross-linking analysis, including photoaffinity labeling, with the aid of chemical cross-linkers has also been used, leading to partly successful results with a restricted range of clustered molecules. Morphological visualization with fluorescence microscopy or electron microscopy has been used to obtain useful findings. However, all target molecules of these approaches need to be known at the starting points. Compared with these current methods, EMARS is a very powerful approach. The advantages of this approach can be summarized as follows: (a) using living cells to analyze events on the cell surface, corresponding to the size of microdomains; (b) no need for special equipment, and easy to carry out; and (c) applicable for comprehensive analysis of clustering molecules with particular targets, enabling the identification of molecular profiles including those of unknown molecules. 24 Using "cancer-specific" mAbs, we have identified candidate molecules that might physically and functionally interact with cancer-associated glycosphingolipids on the cell surface within ca.
300 nm, as shown in Figure 3 . 23, 24 Thus, how glycosphingolipids are 
| C AN CER-A SSO CIATED G LYCOS PHING OLIPIDS PL AY ROLE S THROUG H COMPLE X FORMATI ON WITH MEMB R ANE MOLECULE S
As described above, ganglioside GD3 has been considered as a melanoma-specific glycolipid antigen, 25 and been used as a target of Ab therapy and/or immune cell-mediated therapy for malignant melanomas. 26, 27 Roles of GD3 in melanomas have been reported based on experiments using cells transfected with GD3 synthase cDNA, showing its effects on the activation of signaling molecules located downstream of growth factor receptors 28 or adhesion receptors, integrins. 17 An EMARS/MS analysis ( Figure 3 ) with melanoma cells using anti-GD3 mAb revealed various membrane molecules as candidate molecules that associate with GD3. 29 Among them, Neogenin-1 was defined as a GD3-associating molecule and also as a GEM/raft-residing molecule exclusively in GD3 + cells. Using a replication-competent avian leukemia virus splice acceptor system, 31 we analyzed murine gliomas with a focus on the expression of gangliosides on the cell surface. 32 Astrocytes transfected with GD2 expression on astrocytes. Thus, it was shown that GD3/GD2 expression increased cell growth, invasion, and migration. To clarify the mechanisms by which GD3/GD2 enhance the malignant properties of gliomas, EMARS/MS was carried out, and PDGFRα was defined as a GD3-associating molecule in murine gliomas. 32 Only GD3 formed a molecular complex with PDGFRα, and the Src family Yes was also included in the complex, leading to the formation of a ternary molecular complex adjacent to the cell membrane. 32 This complex activated paxillin, 32 resulting in the increased invasiveness that is the most notable feature of gliomas 33 ( Figure 5A ).
Application of the EMARS/MS approach resulted in the detection of GD3-associating molecules in human melanoma and murine glioma cells, both of which are membrane receptors that regulate cell growth/differentiation. In contrast, a similar approach led to the detection of an amino acid transporter in SCLC.
Among human lung cancers, SCLC show high frequencies of metastasis and recurrence. Therefore, novel Ab therapy targeting SCLC-specific antigens has been long expected. 34 As a result of EMARS/MS using anti-GD2 mAb and GD2 synthase-transfectants of SK-LC-17, 9 approximately 20 molecules were identified as candidates of GD2-associating molecules. 35 These molecules consisted of CD109, uPAR, EphA2, and CD44. Among them, ASCT2, a glutamine transporter, was most clearly localized in lipid rafts of GD2 + cells. Then we examined roles of ASCT2 in SCLC cells.
The expression of ASCT2 in SCLC cells resulted in increased proliferation and invasion. ASCT2 colocalized with GD2 in GEM/rafts, and they were associated with each other, as shown by multiple approaches such as co-immunoprecipitation and the proximity ligation assay. 35 Consequently, ASCT2 co-operated with GD2 and increased the uptake of glutamine, and increased activation levels of downstream molecules of mTOR1, such as p-p70 S6K1 and p-S6 35 ( Figure 5B ). Antibodies specific for particular glycolipids are labeled with HRP directly or indirectly (secondary Ab), and then biotin-conjugated aryl azide is added, resulting in the biotin labeling of membrane molecules present around target glycolipids (within 200-300 nm). These molecules are applied to MS to identify the proteins and aid functional analysis, such as interaction and cooperation with glycolipid antigens. B, An representative EMARS reaction is shown, in which the reaction was carried out using anti-ganglioside GD2 mAb for small-cell lung cancer (SCLC) cells. Labeled proteins were immunoprecipitated and applied for immunoblotting. Only the sample labeled with the anti-GD2 mAb showed multiple bands. 35 These proteins were applied to MS F I G U R E 5 Action of ganglioside-associating molecules defined by enzyme-mediated activation of radical sources/mass spectrometry (EMARS/MS) analysis in murine gliomas and human small-cell lung cancer (SCLC) cells. A, Platelet-derived growth factor receptor-α (PDGFRα) was defined as a GD3-associating molecule in murine gliomas by the EMARS/MS approach. Specific association of GD3 with PDGFRα was identified by co-immunoprecipitation, and activated Yes was also found in the immune complex. Subsequently, it was shown that membrane molecular complexes consisting of GD3, PDGFRα and Yes promote glioma invasiveness by activating paxillin. 32 B, By EMARS/MS, a glutamine transporter, ASCT2, was defined as a GD2-associating molecule in SCLC. ASCT2 cooperates with GD2, resulting in the increased activation levels of mTOR1 downstream molecules such as p70S6K1 and S6 in SCLC cells. 35 These signals finally induce increased cell growth and migration
| G LYCOS PHING OLIPIDS REG UL ATE ARCHITEC TURE AND FUN C TI ON OF G EM/ R AF TS
The majority of the cancer-associated glycosphingolipids mentioned above are considered to localize in GEM/rafts. Indeed, many of the EMARS/MS-defined molecules targeting glycosphingolipids were detected in GEM/rafts. 29, 36 Among GEM/raft-residing molecules, such as cholesterol, sphingomyelin, GPI-anchored proteins, and glycosphingolipids, the latter 2 are unique as they make up relatively uniform lipids and polymorphic nonlipid portions. 36 The polymorphic portions, ie, proteins or carbohydrates, are exposed to the outside of the cell surface, interacting with outward ligands. Glycosphingolipids are particularly unique because they interact with outward ligands, but also with cis-residing molecules on the same cell membrane, playing roles by forming molecular complexes consisting of assembled glycolipids and membrane molecules. from GEM/rafts in mouse brain tissues. 37 Thus, expression patterns of glycosphingolipids determine the features of GEM/rafts, ie, profiles of GEM/rafts and properties of GEM/rafts as a platform for signal regulation. Lipid rafts have been considered to take part in the complex protein-protein interactions for the generation of signal transduction. 38 Lipid rafts can change size (from nanoscale to raft "phase") and composition responding to intra-or extracellular stimuli, as shown in Figure 6 . 39 Therefore, how altered carbohydrates in cancer cells regulate the composition and function of GEM/rafts and cell signals, and whether individual cancer-associated glycosphingolipids form distinct molecular clusters and exert unique signaling, remain to be clarified in the future.
| DE VELOPMENT OF NOVEL TECHNOLOGY ENAB LE S US TO FURTHER UNDER S TAND G LYCOS PHING OLIPIDS
In addition to the EMARS/MS approach, development of novel technologies has brought about a new era of cancer-associated glycosphingolipids. Single molecule imaging with high resolution (millisecond scale) has made it possible to observe the spatiotemporal dynamics of molecular clustering on cell surfaces. 40 It has become possible to observe processes of actual formation of molecular complexes on the cell surface. 40 The results of these imaging experiments have been markedly changing the concept of GEM/rafts. Minimal units of nanoscale GEM/rafts might be dimer formation of glycosphingolipids with the same structure, 41 whereas GPI-anchored proteins should play central roles in the solid and microscale membrane domains. 42 For a long time, glycosphingolipids have been considered to be regulatory molecules, particularly in the nervous system, mainly because of their abundant expression in neuronal cells. 46 However, it was reported that fine structures of glycosphingolipids are not essential for the existence of bio-organisms, but they are pivotal regulators of various cells and organs based on the regulation of cell signals in GEM/rafts. 47 What should be emphasized here is that the cluster formation of glycosphingolipids with homopolymer mode could be critical for recognition by ligand molecules. Recently, heteropolymers have also been reported to sometimes be essential for interactions with cis-and trans-acting ligands such as lectins. [48] [49] [50] These molecular clusters in GEM/rafts should affect the assembly/ dispersion of other membrane molecules in/from GEM/rafts, 51 leading to the functional regulation of those membrane molecules. 51, 52, 53 Furthermore, molecular complex formation in a vertical direction through the cell membrane is also crucial for the determination of cell fates. Now, glycosphingolipids are emerging as regulators of membrane environments and cancer microenvironments, not just markers of cell differentiation and malignant transformation.
Based on novel findings on the functions and modes of action of cancer-associated glycosphingolipids, novel therapeutic trials have been carried out, or considered. 54 For example, when a novel signaling pathway activated by cancer-associated glycosphingolipids is found, key molecules in the pathway could be targets of therapy. In fact, p130Cas and paxillin, which are activated in GD3 + melanomas, were examined as possible target molecules for siRNA therapy. 55 Membrane proteins that are identified as partners of cancer-associated glycolipids might be better targets for treatment.
Downstream signal molecules of these partner membrane molecules could be more specific for cancer cells. Furthermore, identification of new epitopes formed by molecular complexes consisting of cancerassociated glycolipids and their partners might be expected as new targets. If particular molecules in glycosylation machineries are considered to be cancer-specific, and to play key roles, they could also be new targets of cancer therapy.
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